Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
SAN MATEO, Calif., Feb. 12, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...
SAN MATEO, Calif., Feb. 9, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...
VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count--...
--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020...
--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan...
VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution,...
VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution,...
- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER, BC, Nov. 5, 2020 /PRNewswire/ ...
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - VANCOUVER, BC, Nov. 5, 2020 /PRNewswire/ - Sierra...
VANCOUVER, BC, Oct. 2, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...
VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...
- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC,...
- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of...
- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable...
- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m....
- Mr. Craig Collard appointed to the Board of Directors - VANCOUVER, May 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...
- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity -...
- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th - VANCOUVER, May 7, 2020 /PRNewswire/ ...
- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially...
- MOMENTUM Phase 3 clinical trial for momelotinib underway, targeting enrolment of 180 patients with myelofibrosis who are symptomatic and anemic - - ...
VANCOUVER, Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...
-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER, Feb. 25, 2020 /PRNewswire/ - Sierra...
VANCOUVER, Feb. 6, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and...
- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.